Naoto Kuroda, MD, of Wayne State University, in Detroit, Michigan, provided a checklist for clinicians about what they should ask and look out for in a telemedicine session with patients with epilepsy.
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
A brief communication provides information about the associations between, and the considerations for, COVID-19 and epilepsy.
The STOPBAG2 scoring instrument, which incorporates sleep-related symptoms and continuous variables for age and BMI, offers greater discriminatory power for predicting all levels of OSA severity in adults with epilepsy.
In patients with a known diagnosis of cirrhosis, hepatic exacerbations may increase the risk for hospitalization for epilepsy and status epilepticus.
Self-monitoring behaviors may serve as a potential mediator of therapeutic change for patients with epilepsy.
The FDA has approved Valtoco (diazepam nasal spray; Neurelis) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.
Researchers established a prediction model based on the additive effect of 4 independent factors that form an accurate model for predicting the risk of drug-resistant epilepsy in children with cerebral palsy.
This study described data collected from patients who self-selected to participate in the Cleveland Clinic Epilepsy Center’s virtual follow-up program.
Children with pediatric epilepsy who undergo surgery may experience long-term changes in verbal and nonverbal IQ.
